Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281601 · ClinicalTrials.gov registry record · Phase 1
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT05281601 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 46 participants.
The verdict
NCT05281601, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to \< 18 years.
Interventions
- DRUG AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2024-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281601
The ClinicalTrials.gov registry entry for NCT05281601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD7442 is the first listed.
NCT05281601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05281601 about?
NCT05281601 is a clinical study titled "AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics". This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to \< 18 years.
What is the current status of trial NCT05281601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-03-21. Estimated completion is 2024-04-16.
What interventions are being tested in trial NCT05281601?
The interventions under investigation include: AZD7442 (DRUG).
Who is sponsoring clinical trial NCT05281601?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.